SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Chimerix, Inc. Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Your Message